TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 Secondary Research Data Flow:
3.5 PRIMARY RESEARCH:
3.5.1 Primary Research Data Flow:
3.5.2 Primary Research: Number of Interviews conducted
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
3.7.1 Data forecasting Technique
3.8 DATA MODELLING
3.8.1 Microeconomic Factor Analysis:
3.8.2 Data MODELLING:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 Increasing Funding For Genetic Research.
4.2.2. Rising Incidence Of Genetic Disorders.
4.3 RESTRAINTS
4.4 OPPORTUNITY
4.4.1 Increasing Applications Of Areas Of Gene Editing.
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 Threat of New Entrants
5.1.2 Bargaining Power Of Suppliers
5.1.3 Threat of Substitutes
5.1.4 Bargaining Power of Buyers
5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE GENE EDITING MARKET
6 GENE EDITING MARKET, BY TECHNOLOGY
6.1 OVERVIEW
6.2 CRISPER
6.3 TALEN
6.4 ZFEN
6.5 Antisense
6.6 Others
7 GENE EDITING MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 Genetic Engineering
7.2.1 Cell Line Engineering
7.2.2 Animal Genetic Engineering
7.2.3 Plant Genetic Engineering
7.2.4 Others
7.3 Clinical Applications
7.3.1 Diagnostics
7.3.2 Therapy Development
7.4 Others
8 GENE EDITING MARKET, BY METHOD
8.1 OVERVIEW
8.2 Ex-vivo
8.3 In-vivo
9 GENE EDITING MARKET, BY END USERS
9.1 OVERVIEW
9.2 Biotechnology and Pharmaceutical Companies
9.3 Contract Research Organizations (CROs)
9.4 Academic and Government Research Institutes.
10 GENE EDITING MARKET, BY REGION
10.1 OVERVIEW
10.2 North America
10.2.1 US
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 UK
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 South Korea
10.4.5 Australia
10.4.6 Rest of Asia Pacific
10.5 Rest of World
10.5.1 Middle East
10.5.2 Africa
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, 2022
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.6.1 product approval
12 COMPANY PROFILES
12.1 GE HEALTHCARE. (US)
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
13.2 THERMO FISHER SCIENTIFIC INC. (US)
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCTS OFFERED
13.2.4 KEY DEVELOPMENTS
13.2.5 KEY STRATEGIES
14.3 BIO-RAD LABORATORIES INC.(US)
14.3.1 COMPANY OVERVIEW
14.3.2 FINANCIAL OVERVIEW
14.3.3 PRODUCTS OFFERED
14.3.4 KEY DEVELOPMENTS
14.3.5 KEY STRATEGIES
15.4 LONZA (SWITZERLAND)
15.4.1 COMPANY OVERVIEW
15.4.2 FINANCIAL OVERVIEW
15.4.3 PRODUCTS OFFERED
15.4.4 KEY DEVELOPMENTS
15.4.5 SWOT ANALYSIS
15.4.6 KEY STRATEGIES
16.5 GENSCRIPT (US)
16.5.1 COMPANY OVERVIEW
16.5.2 FINANCIAL OVERVIEW
16.5.3 Products OFFERed
16.5.4 KEY DEVELOPMENTS
16.5.5 KEY STRATEGIES
17.6 HORIZON DISCOVERY LTD. (UK)
17.6.1 COMPANY OVERVIEW
17.6.2 FINANCIAL OVERVIEW
17.6.3 Products OFFERed
17.6.4 KEY DEVELOPMENTS
17.6.5 KEY STRATEGIES
18.7 ORIGENE TECHNOLOGIES INC. (US)
18.7.1 COMPANY OVERVIEW
18.7.2 FINANCIAL OVERVIEW
18.7.3 Products OFFERed
18.7.4 KEY DEVELOPMENTS
18.7.5 KEY STRATEGIES
19.8 INTEGRATED DNA TECHNOLOGIES INC. (US)
19.8.1 COMPANY OVERVIEW
19.8.2 FINANCIAL OVERVIEW
19.8.3 productS OFFERED
19.8.4 KEY DEVELOPMENTS
19.8.5 SWOT ANALYSIS
19.8.6 KEY STRATEGIES
20.9 NEW ENGLAND BIOLABS INC. (US)
20.9.1 COMPANY OVERVIEW
20.9.2 FINANCIAL OVERVIEW
20.9.3 products OFFERED
20.9.4 KEY DEVELOPMENTS
20.9.5 SWOT ANALYSIS
20.9.6 KEY STRATEGIES
21.10 SANGAMO THERAPEUTICS (US)
21.10.1 COMPANY OVERVIEW
21.10.2 FINANCIAL OVERVIEW
21.10.3 products OFFERED
21.10.4 KEY DEVELOPMENTS
21.10.5 SWOT ANALYSIS
21.10.6 KEY STRATEGIES
12 DATA CITATIONS
LIST OF TABLES
TABLE 1 QFD MODELLING FOR MARKET SHARE ASSESSMENT
TABLE 2 GENE EDITING MARKET, BY TECHNOLOGY, 2019–2032 (USD BILLION)
TABLE 3 GENE EDITING, BY APPLICATION, 2019–2032 (USD BILLION)
TABLE 4 GENE EDITING MARKET, BY METHOD, 2019–2032 (USD BILLION)
TABLE 5 GENE EDITING, BY END USER, 2019–2032 (USD BILLION)
TABLE 6 GENE EDITING, BY REGION, 2019–2032 (USD BILLION)
TABLE 7 PUBLIC PLAYERS STOCK SUMMARY
TABLE 8 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 9 PRODUCT APPROVAL
TABLE 10 GE HEALTHCARE INC. (US): PRODUCTS OFFERED
TABLE 11 THERMO FISHER SCIENTIFIC INC. (US): PRODCUTS OFFERED
TABLE 12 BIO-RAD LABORATORIES INC. (US): PRODUCTS OFFERED
TABLE 13 LONZA (SWITZERLAND): PRODUCTS OFFERED
TABLE 14 GENSCRIPT (US): PRODUCTS OFFERED
TABLE 15 HORIZRN DISCOVERY LTD. (UK): PRODUCTS OFFERED
TABLE 16 ORIGENE TECHNOLOGIES INC. (US): PRODUCTS OFFERED
TABLE 17 INTEGRATED DNA TECHNOLOGIES INC. (US): PRODUCTS OFFERED
TABLE 18 NEW ENGLAND BIOLABS INC. (US): PRODUCTS OFFERED
TABLE 19 SANGAMO THERAPEUTICS (US): PRODUCTS OFFERED
LIST OF FIGURES
FIGURE 1 GENE EDITING MARKET: STRUCTURE
FIGURE 2 GENE EDITING MARKET REPORT: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GENE EDITING MARKET
FIGURE 6 GENE EDITING MARKET, BY TECHNOLOGY, 2019 & 2032 (USD BILLION)
FIGURE 7 GENE EDITING MARKET SHARE (%), BY TECHNOLOGY, 2023
FIGURE 8 GENE EDITING MARKET T, BY APPLICATION, 2019 & 2032 (USD BILLION)
FIGURE 9 GENE EDITING MARKET SHARE (%), BY APPLICATION, 2023
FIGURE 10 GENE EDITING MARKET, BY METHOD, 2019 & 2032 (USD BILLION)
FIGURE 11 GENE EDITING MARKET SHARE (%), BY METHOD, 2023
FIGURE 12 GENE EDITING MARKET, BY END USER, 2019 & 2032 (USD BILLION)
FIGURE 13 GENE EDITING MARKET SHARE (%), BY END USER, 2023
FIGURE 14 GENE EDITING MARKET, BY REGION, 2019 & 2032 (USD BILLION)
FIGURE 15 GENE EDITING MARKET SHARE (%), BY REGION, 2023
FIGURE 16 GENE EDITING MARKET PLAYERS: COMPETITIVE ANALSIS, 2023
FIGURE 17 COMPETITOR DASHBOARD: GENE EDITING MARKET
FIGURE 18 GE HEALTHCARE (US): FINANCIAL OVERVIEW
FIGURE 19 GE HEALTHCARE. (US): SWOT ANALYSIS
FIGURE 20 THERMO FISHER SCIENTIFIC INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 THERMO FISHER SCIENTIFIC INC. (US): SWOT ANALYSIS
FIGURE 22 BIO-RAD LABORATORIES INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 BIO-RAD LABORATORIES INC. (US): SWOT ANALYSIS
FIGURE 24 LONZA (SWITZERLAND).: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 LONZA (SWITZERLAND): SWOT ANALYSIS
FIGURE 26 GENSCRIPT (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 GENSCRIPT (US): SWOT ANALYSIS
FIGURE 28 HORIZON DISCOVERY LTD. (UK): FINANCIAL OVERVIEW
FIGURE 29 HORIZON DISCOVERY LTD. (UK): SWOT ANALYSIS
FIGURE 30 ORIGENE TECHNOLOGIES INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 ORIGENE TECHNOLOGIES INC. (US): SWOT ANALYSIS
FIGURE 32 INTEGRATED DNA TECHNOLOGIES INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 INTEGRATED DNA TECHNOLOGIES INC. (US): SWOT ANALYSIS
FIGURE 34 NEW ENGLAND BIOLABS INC. (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 NEW ENGLAND BIOLABS INC. (US): SWOT ANALYSIS
FIGURE 36 SANGAMO THERAPEUTICS (US): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 SANGAMO THERAPEUTICS (US): SWOT ANALYSIS 
1 DATA CITATIONS
